Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

New treatment strategies for HPV-positive head and neck cancer.

Kofler B, Laban S, Busch CJ, Lörincz B, Knecht R.

Eur Arch Otorhinolaryngol. 2014 Jul;271(7):1861-7. doi: 10.1007/s00405-013-2603-0. Epub 2013 Aug 10. Review.

PMID:
23934317
2.

Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.

Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A, Anderson ME, Lee JH.

Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1137-46. doi: 10.1001/archoto.2009.159.

PMID:
19917928
3.

Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection.

López RV, Levi JE, Eluf-Neto J, Koifman RJ, Koifman S, Curado MP, Michaluart-Junior P, Figueiredo DL, Saggioro FP, de Carvalho MB, Kowalski LP, Abrahão M, de Góis-Filho F, Tajara EH, Waterboer T, Boffetta P, Brennan P, Wünsch-Filho V.

Cancer Causes Control. 2014 Apr;25(4):461-71. doi: 10.1007/s10552-014-0348-8. Epub 2014 Jan 29.

PMID:
24474236
4.

Current treatment options for metastatic head and neck cancer.

Price KA, Cohen EE.

Curr Treat Options Oncol. 2012 Mar;13(1):35-46. doi: 10.1007/s11864-011-0176-y. Review.

PMID:
22252884
5.

Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines.

Nagel R, Martens-de Kemp SR, Buijze M, Jacobs G, Braakhuis BJ, Brakenhoff RH.

Oral Oncol. 2013 Jun;49(6):560-6. doi: 10.1016/j.oraloncology.2013.03.446. Epub 2013 Apr 8.

6.

Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.

Salazar CR, Smith RV, Garg MK, Haigentz M Jr, Schiff BA, Kawachi N, Anayannis N, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF.

Head Neck Pathol. 2014 Mar;8(1):77-87. doi: 10.1007/s12105-013-0486-4. Epub 2013 Sep 4.

7.

Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.

Schultz JD, Mühlheim K, Erben P, Hofheinz RD, Faber A, Thorn C, Sommer JU, Hörmann K, Sauter A.

Oncol Rep. 2011 Nov;26(5):1099-109. doi: 10.3892/or.2011.1403. Epub 2011 Jul 26.

PMID:
21805039
8.

Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma.

Cooper T, Biron VL, Fast D, Tam R, Carey T, Shmulevitz M, Seikaly H.

J Otolaryngol Head Neck Surg. 2015 Feb 24;44:8. doi: 10.1186/s40463-015-0062-x.

9.

Human papillomavirus-related head and neck tumors: clinical and research implication.

Psyrri A, Gouveris P, Vermorken JB.

Curr Opin Oncol. 2009 May;21(3):201-5. Review.

PMID:
19370803
10.

Population-based evidence of increased survival in human papillomavirus-related head and neck cancer.

Nygård M, Aagnes B, Bray F, Møller B, Mork J.

Eur J Cancer. 2012 Jun;48(9):1341-6. doi: 10.1016/j.ejca.2012.03.014. Epub 2012 Apr 18.

PMID:
22516210
11.

Human papillomavirus predicts the outcome following concomitant chemoradiotherapy in patients with head and neck squamous cell carcinomas.

Duray A, Descamps G, Decaestecker C, Sirtaine N, Gilles A, Khalifé M, Chantrain G, Depuydt CE, Delvenne P, Saussez S.

Oncol Rep. 2013 Jul;30(1):371-6. doi: 10.3892/or.2013.2415. Epub 2013 Apr 22.

PMID:
23603900
12.

Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma.

Geiger JL, Lazim AF, Walsh FJ, Foote RL, Moore EJ, Okuno SH, Olsen KD, Kasperbauer JL, Price DL, Garces YI, Ma DJ, Neben-Wittich MA, Molina JR, Garcia JJ, Price KA.

Oral Oncol. 2014 Apr;50(4):311-8. doi: 10.1016/j.oraloncology.2014.01.001. Epub 2014 Jan 24.

PMID:
24467937
13.

[HPV infection in head and neck squamous cell carcinoma (HNSCC). Highlights from ASCO 2010].

Ihloff AS, Knecht R, Tribius S.

HNO. 2010 Dec;58(12):1163-7. doi: 10.1007/s00106-010-2200-0. Review. German.

PMID:
20963389
14.

[Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer].

Wittekindt C, Wagner S, Mayer CS, Klußmann JP.

Laryngorhinootologie. 2012 Mar;91 Suppl 1:S1-26. doi: 10.1055/s-0031-1297241. Epub 2012 Mar 28. Review. German.

PMID:
22456913
15.

Predictive Factors for Outcome and Quality of Life in HPV-Positive and HPV-Negative HNSCC.

Hess J.

Recent Results Cancer Res. 2017;206:233-242. Review.

PMID:
27699543
16.

HPV & head and neck cancer: a descriptive update.

Goon PK, Stanley MA, Ebmeyer J, Steinsträsser L, Upile T, Jerjes W, Bernal-Sprekelsen M, Görner M, Sudhoff HH.

Head Neck Oncol. 2009 Oct 14;1:36. doi: 10.1186/1758-3284-1-36. Review.

17.

The pathology of HPV-related head and neck cancer: implications for the diagnostic pathologist.

Westra WH.

Semin Diagn Pathol. 2015 Jan;32(1):42-53. doi: 10.1053/j.semdp.2015.02.023. Epub 2015 Feb 27. Review.

PMID:
25804343
18.

Quality of life in head and neck cancer patients: impact of HPV and primary treatment modality.

Maxwell JH, Mehta V, Wang H, Cunningham D, Duvvuri U, Kim S, Johnson JT, Ferris RL.

Laryngoscope. 2014 Jul;124(7):1592-7. doi: 10.1002/lary.24508. Epub 2013 Dec 18.

PMID:
24353066
19.

Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.

Harris M, Wang XG, Jiang Z, Goldberg GL, Casadevall A, Dadachova E.

Head Neck Oncol. 2011 Feb 12;3(1):9. doi: 10.1186/1758-3284-3-9.

20.

Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).

Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS.

Head Neck Oncol. 2010 Jun 29;2:15. doi: 10.1186/1758-3284-2-15. Review.

Supplemental Content

Support Center